Akrimax Pharmaceuticals, LLC

akrimax.com

At Akrimax Pharmaceuticals, we manufacture and market pharmaceutical products with unique and meaningful clinical advantages that improve the lives of patients. Our current commercial portfolio is focused in the areas of cardiovascular medicine, endocrinology and pain management. Akrimax is a sales and marketing company. Our mission is to acquire and commercialize under-promoted, under-utilized pharmaceutical products and those in late stage clinical development.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

ATHIRA PHARMA ADVANCES PHASE 2/3 LIFT-AD CLINICAL STUDY OF FOSGONIMETON IN MILD-TO-MODERATE ALZHEIMER’S PATIENTS

Athira Pharma, Inc. | October 18, 2022

news image

Athira Pharma, Inc. a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that following an unblinded interim efficacy and futility analysis, an independent data monitoring committee recommended continuation of the LIFT-AD study of fosgonimeton in patients with mild-to-moderate Alzheimer’s disease. The committee also determined that, with the additional enrollment of fewer than 150 patien...

Read More

Business Insights

TRIMAS ANNOUNCES TWO NEW ACQUISITIONS

TriMas | December 14, 2021

news image

TriMas announced that it has recently signed agreements to acquire Omega Plastics to be added to TriMas Packaging, and TFI Aerospace to be added to TriMas Aerospace. Omega, located in Clinton Township, Michigan, specializes in manufacturing custom components and devices for drug delivery, diagnostic and orthopedic medical applications, as well as components for industrial applications. Omega leverages its advanced in-house tool making capabilities, ISO13485-certified injecti...

Read More

Business Insights

IKTOS ANNOUNCES COLLABORATION WITH GALAPAGOS IN AI FOR DRUG DESIGN

Iktos, | June 29, 2022

news image

Iktos, a company specialized in Artificial Intelligence for new drug design, announced a collaboration with Galapagos, a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, to apply Iktos’s generative modelling artificial intelligence (AI) technology in one of Galapagos drug discovery programs. Under the agreement, Iktos will apply its de novo ligand and structure-based generative modelling technologies and software ...

Read More

Pharma Tech

XTALPI ANNOUNCES COLLABORATION WITH LILLY, USING AI + ROBOTICS TO UNCOVER FIRST-IN-CLASS THERAPEUTICS

PRNewswire | May 31, 2023

news image

Today, XtalPi Inc., a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, announced an AI drug discovery collaboration of up to $250 million in upfront and milestone payments with Eli Lilly and Company. The collaboration will leverage XtalPi's integrated AI capabilities and robotics platform to de novo design and deliver drug candidates for an undisclosed target. XtalPi has established itself as an industry leader in combining...

Read More
news image

Business Insights

ATHIRA PHARMA ADVANCES PHASE 2/3 LIFT-AD CLINICAL STUDY OF FOSGONIMETON IN MILD-TO-MODERATE ALZHEIMER’S PATIENTS

Athira Pharma, Inc. | October 18, 2022

Athira Pharma, Inc. a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that following an unblinded interim efficacy and futility analysis, an independent data monitoring committee recommended continuation of the LIFT-AD study of fosgonimeton in patients with mild-to-moderate Alzheimer’s disease. The committee also determined that, with the additional enrollment of fewer than 150 patien...

Read More
news image

Business Insights

TRIMAS ANNOUNCES TWO NEW ACQUISITIONS

TriMas | December 14, 2021

TriMas announced that it has recently signed agreements to acquire Omega Plastics to be added to TriMas Packaging, and TFI Aerospace to be added to TriMas Aerospace. Omega, located in Clinton Township, Michigan, specializes in manufacturing custom components and devices for drug delivery, diagnostic and orthopedic medical applications, as well as components for industrial applications. Omega leverages its advanced in-house tool making capabilities, ISO13485-certified injecti...

Read More
news image

Business Insights

IKTOS ANNOUNCES COLLABORATION WITH GALAPAGOS IN AI FOR DRUG DESIGN

Iktos, | June 29, 2022

Iktos, a company specialized in Artificial Intelligence for new drug design, announced a collaboration with Galapagos, a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, to apply Iktos’s generative modelling artificial intelligence (AI) technology in one of Galapagos drug discovery programs. Under the agreement, Iktos will apply its de novo ligand and structure-based generative modelling technologies and software ...

Read More
news image

Pharma Tech

XTALPI ANNOUNCES COLLABORATION WITH LILLY, USING AI + ROBOTICS TO UNCOVER FIRST-IN-CLASS THERAPEUTICS

PRNewswire | May 31, 2023

Today, XtalPi Inc., a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, announced an AI drug discovery collaboration of up to $250 million in upfront and milestone payments with Eli Lilly and Company. The collaboration will leverage XtalPi's integrated AI capabilities and robotics platform to de novo design and deliver drug candidates for an undisclosed target. XtalPi has established itself as an industry leader in combining...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us